Ann Lab Med.  2014 Mar;34(2):170-173. 10.3343/alm.2014.34.2.170.

Pyrosequencing as a Fast and Reliable Method in Detecting the MYD88 p.L265P Mutation in Decalcified Formalin-Fixed and Paraffin-Embedded Tissues

• Gebauer N
• Bernard V
• Rohner C
• Krokowski
• Merz H
• Feller AC
• Thorns C

• KMID: 1791915
• DOI: http://doi.org/10.3343/alm.2014.34.2.170

Abstract

No abstract available.

MeSH Terms

Adult
Aged
Base Sequence
Bone Marrow/metabolism/pathology
Female
Formaldehyde/chemistry
Gene Frequency
Humans
Male
Middle Aged
Multiple Myeloma/diagnosis/genetics
Mutation
Myeloid Differentiation Factor 88/chemistry/*genetics/metabolism
Paraffin Embedding
Sequence Analysis, DNA/*methods
Waldenstrom Macroglobulinemia/diagnosis/genetics
Formaldehyde
Myeloid Differentiation Factor 88

Figure

• 

  Fig. 1 Bone marrow trephine biopsy and smear from a case of Waldenström's macroglobulinemia harboring the MYD88 p.L265P mutation with an allele frequency of 46% as determined by pyrosequencing assay (A), and a patient suffering from multiple myeloma without the MYD88 p.L265P mutation (B) (hematoxylin-eosin, ×200, Pappenheim stain, ×400). Corresponding quantification of allele burden using the PyroMark software in the above cases of Waldenström's macroglobulinemia (C) and multiple myeloma (D).

Reference

1. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470:115–119. PMID: 21179087.

2. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012; 367:826–833. PMID: 22931316.

3. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013; 121:2051–2058. PMID: 23321251.

4. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013; 121:4504–4511. PMID: 23532735.

5. Loiarro M, Ruggiero V, Sette C. Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MYD88 inhibitors. Clin Lymphoma Myeloma Leuk. 2013; 13:222–226. PMID: 23490990.

6. Wang CZ, Lin J, Qian J, Shao R, Xue D, Qian W, et al. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. Clin Biochem. 2013; 46:385–387. PMID: 23178471.

7. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol. 2006; 169:471–481. PMID: 16877349.